PENTRAXIN 3 AND C-REACTIVE PROTEIN IN SEVERE MENINGOCOCCAL DISEASE
暂无分享,去创建一个
A. Mantovani | J. V. D. van der Meer | M. van Deuren | T. Sprong | J. van der Meer | S. Signorini | G. Peri | C. Neeleman
[1] T. Calandra,et al. MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) IN MENINGOCOCCAL SEPTIC SHOCK AND EXPERIMENTAL HUMAN ENDOTOXEMIA , 2007, Shock.
[2] B. Han,et al. Long pentraxin 3 in pulmonary infection and acute lung injury. , 2007, American journal of physiology. Lung cellular and molecular physiology.
[3] Barbara Bottazzi,et al. Pentraxins in Innate Immunity: From C-Reactive Protein to the Long Pentraxin PTX3 , 2007, Journal of Clinical Immunology.
[4] C. Garlanda,et al. Regulation of PTX3, a key component of humoral innate immunity in human dendritic cells: stimulation by IL‐10 and inhibition by IFN‐γ , 2006, Journal of leukocyte biology.
[5] P. Pickkers,et al. VASCULAR ENDOTHELIAL GROWTH FACTOR IS INCREASED DURING THE FIRST 48 HOURS OF HUMAN SEPTIC SHOCK AND CORRELATES WITH VASCULAR PERMEABILITY , 2005, Shock.
[6] A. Mantovani,et al. Elevated plasma levels of the long pentraxin, pentraxin 3, in severe dengue virus infections , 2005, Journal of medical virology.
[7] A. Agrawal. CRP after 2004. , 2005, Molecular immunology.
[8] Pascale Jeannin,et al. Complexity and complementarity of outer membrane protein A recognition by cellular and humoral innate immunity receptors. , 2005, Immunity.
[9] P. Brandtzaeg,et al. Chemokine patterns in meningococcal disease. , 2005, The Journal of infectious diseases.
[10] J. G. van der Hoeven,et al. Microvascular permeability during experimental human endotoxemia: an open intervention study , 2005 .
[11] M. Baker,et al. Fever in the new millennium: a review of recent studies of markers of serious bacterial infection in febrile children , 2005, Current opinion in pediatrics.
[12] C. Garlanda,et al. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. , 2005, Annual review of immunology.
[13] J. Casado‐flores,et al. Prognostic utility of the semi-quantitative procalcitonin test, neutrophil count and C-reactive protein in meningococcal infection in children , 2005, European Journal of Pediatrics.
[14] A. Mantovani,et al. The long pentraxin PTX3 up‐regulates tissue factor in activated monocytes: another link between inflammation and clotting activation , 2004, Journal of leukocyte biology.
[15] B. Jilma,et al. Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia , 2004, Critical care medicine.
[16] S. Calvano,et al. Effects of Drotrecogin Alfa (Activated) in Human Endotoxemia , 2004, Shock.
[17] D. J. Unsworth,et al. The immunopathogenesis of meningococcal disease , 2003, Journal of clinical pathology.
[18] W. Hop,et al. Procalcitonin as a prognostic marker in meningococcal disease , 2002, Intensive Care Medicine.
[19] A. Mantovani,et al. Long Pentraxin PTX3 Upregulates Tissue Factor Expression in Human Endothelial Cells: A Novel Link Between Vascular Inflammation and Clotting Activation , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[20] A. Mantovani,et al. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. , 2001, Arthritis and rheumatism.
[21] J. Volanakis,et al. Human C-reactive protein: expression, structure, and function. , 2001, Molecular immunology.
[22] V. Torri,et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients , 2001, Critical care medicine.
[23] G Olivetti,et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. , 2000, Circulation.
[24] A. J. van Vught,et al. Pediatric risk of mortality (PRISM) score in meningococcal disease , 2000, European Journal of Pediatrics.
[25] J. V. D. van der Meer,et al. Update on meningococcal disease with emphasis on pathogenesis and clinical management. , 2000, Clinical microbiology reviews.
[26] R. Malley,et al. Clinical and hematologic features do not reliably identify children with unsuspected meningococcal disease. , 1999, Pediatrics.
[27] J. V. D. Meer,et al. Acute meningokokkeninfecties: lage C-reactief proteine (CRP)-concentratie in het serum bij opname wijst op fulminant beloop , 1998 .
[28] Francesco Tedesco,et al. Multimer Formation and Ligand Recognition by the Long Pentraxin PTX3 , 1997, The Journal of Biological Chemistry.
[29] A. Sica,et al. Characterization of the Promoter for the Human Long Pentraxin PTX3 , 1997, The Journal of Biological Chemistry.
[30] T. Blundell,et al. Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. , 1996, Blood.
[31] R. Sauerwein,et al. Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections. , 1995, The Journal of infectious diseases.
[32] J. Robotham,et al. The acute-phase response. , 1995, New horizons.
[33] J. Vilček,et al. Relationship of TSG-14 protein to the pentraxin family of major acute phase proteins. , 1994, Journal of immunology.
[34] A. Mantovani,et al. Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. , 1994, Blood.
[35] A. Whitehead,et al. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. , 1994, Immunology today.
[36] J. Sills,et al. Variation in serum C‐reactive protein across the clinical spectrum of meningococcal disease , 1993, Acta paediatrica.
[37] P. Brandtzaeg,et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. , 1989, The Journal of infectious diseases.
[38] U. Ruttimann,et al. Pediatric risk of mortality (PRISM) score. , 1988, Critical care medicine.
[39] A. Waage,et al. ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASE , 1987, The Lancet.
[40] A. Forrest,et al. Letter: Procaine and malignant hyperthermia. , 1974, Lancet.